Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Distillery Therapeutics

Silencing SOX2 target genes for glioblastoma

BC Staff
November 8, 2022 5:13 PM UTC

Epigenetic silencing of the gene network controlled by the transcription factor SOX2 could help treat glioblastoma multiforme. The epigenetic silencer fuses a version of SOX2 lacking its C-terminal transcriptional activation domain; the Kruppel-associated box (KRAB) domain from the zinc finger protein ZNF10; and the catalytic domain of the DNA methyltransferase DNMT3A, plus its cofactor DNMT3L...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

San Raffaele Scientific Institute